Xtant Medical Holdings, Inc. Announces Record Date for Proposed Rights Offering
BELGRADE, MT / ACCESSWIRE / April 17, 2018 / Xtant™ Medical Holdings, Inc. (NYSE American: XTNT) announced today that it has set April 27, 2018 as the record date for a proposed rights offering of its shares of common stock.At the commencement of the rights offering, each holder of common stock will receive 0.0869816 non-transferable […]
Xtant Announces Fourth Quarter and Year End 2017 Financial Results
BELGRADE, MT / ACCESSWIRE / April 2, 2018 / Xtant™ Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development of regenerative medicine products and medical devices, today reported its financial results for the period ended December 31st, 2017.”2017 represented a significant year for the Company as we completed transformational restructuring activities that were […]
Xtant Medical to Issue Fourth Quarter and Full Year 2017 Financial Results Monday, April 2
BELGRADE, MT / ACCESSWIRE / March 27, 2018 / Xtant Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2017, after the close of the financial markets […]
Xtant Medical Announces Compliance with NYSE American
Reports Pro Forma Stockholders’ Equity of approximately $47.4M as of 2/15/18 Xtant has regained compliance with the NYSE American listing standards BELGRADE, Mont., Feb. 15, 2018 (GLOBE NEWSWIRE) — Xtant™ Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, today reported a positive stockholders’ equity of approximately […]
Xtant Medical Announces Exchange of Outstanding Convertible Notes and Closing of Private Placement
Exchange of $70.238M (plus interest) of convertible notes into 10,401,309 shares of common stock at $7.20 per share. $6.809M Private Placement representing 945,819 shares of common stock at $7.20 per share. BELGRADE, Mont., Feb. 14, 2018 (GLOBE NEWSWIRE) — Xtant™ Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and […]
Xtant Medical Announces Results of Special Meeting of Stockholders
Approval of the issuance of new shares of common stock, as required by the NYSE American. Approval of an amendment to its certificate of incorporation, enabling its previously announced 1:12 reverse stock split. Approval of new directors to serve on its board. BELGRADE, Mont., Feb. 13, 2018 (GLOBE NEWSWIRE) — Xtant™ Medical Holdings, Inc. (NYSE […]
Xtant Medical Enters into Restructuring and Exchange Agreement with All Holders of Outstanding Convertible Notes
Conversion of $1.627M (plus interest) of convertible notes into common stock Exchange of $70.238M (plus interest) of convertible notes into common stock Upon stockholder approval, amendment of Certificate of Incorporation to effect reverse stock split of common stock Private placement of approximately $6.809M of common stock Completion of transaction anticipated to allow Xtant to meet […]
Xtant Medical Reports Third Quarter 2017 Financial Results
Company restructuring efforts continue to gain traction towards profitability Third Quarter 2017 Highlights Reported third quarter 2017 revenue of $19.8 million compared to $23.1 million reported during the third quarter of 2016 Operating Expenses decreased 17% to $14.9 million, compared to $17.9 million reported during the third quarter of 2016 Third quarter 2017 EBITDA of […]
Xtant Medical Postpones Release of Third Quarter 2017 Financial Results
BELGRADE, Mont., Nov. 09, 2017 (GLOBE NEWSWIRE) — Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, announced that it has postponed the release of its third quarter 2017 financial results, originally scheduled for Wednesday, November 8, 2017, and conference call, originally scheduled for Thursday, November […]
Xtant Medical Enters into a Distribution Agreement with curasan, Inc. Bringing Matriform™ to Market
BELGRADE, Mont., Nov. 01, 2017 (GLOBE NEWSWIRE) — Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced it has entered into a distribution agreement with curasan, Inc. adding a premium line of synthetic scaffolds to its biologics portfolio. Matriform, Xtant’s brand of the curasan […]